🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchClinicalTrials.gov GLP-1 trial tracker — updated weekly

ClinicalTrials.gov GLP-1 trial tracker — updated weekly

TrialTracker_MD Mon, Feb 26, 2024 at 4:00 PM 411 replies 11,865 viewsPage 1 of 20
This thread has been pinned by mike_mod.
This thread is more than 27 months old. Information may be outdated. Consider searching for more recent discussions.
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Feb 26, 2024 at 4:00 PM#1

ClinicalTrials.gov GLP-1 trial tracker — updated weekly

Posting this as an important update for the clinical trials & research community. Please read carefully as this may affect your current plans.

I will keep this thread updated as new information becomes available. If you have additional information or corrections, please post below and I will incorporate confirmed updates into this OP.

Key points:

  • This information is current as of the date posted
  • Circumstances may change — always verify independently
  • If you have questions, check if they have been answered in the replies before posting

Bookmarking this thread is recommended — it will be updated as the situation evolves.

— TrialTracker_MD | Clinical Trials & Research
38 16Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 35 others
Reply Quote Save Share Report
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Feb 26, 2024 at 4:14 PM#2
TrialTracker_MD said:
ClinicalTrials.gov GLP-1 trial tracker — updated weekly Posting this as an important update for the clinical trials & research community.

Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.

I would rather be corrected than agreed with, if it comes to it.

39 17NurseKim_ATL, paul_denver, TinaHashiRN and 36 others
Reply Quote Save Share Report
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Feb 26, 2024 at 4:28 PM#3
TrialTracker_MD said:
ClinicalTrials.gov GLP-1 trial tracker — updated weekly Posting this as an important update for the clinical trials & research community.

Pushing back on TrialTracker_MD here. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

Last edited: Feb 26, 2024 at 10:28 PM
40 18sarah_TO, wendy_avl, jason_paloalto and 37 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Feb 26, 2024 at 4:42 PM#4

Answering the narrow version, because the broad one does not have a single answer. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

41 19B12Beth, RickReta_CO, PharmHunterJen and 38 others
Reply Quote Save Share Report
gary_naperville
Member
245
1,123
Oct 2024
Naperville, IL
Feb 26, 2024 at 5:58 PM#5
SarahChen_PharmD said:
Agreed, and subgroup analyses deserve particular suspicion.

Can confirm the pattern SarahChen_PharmD describes. Read four things before the headline number. The population, because trial populations are selected and supported in ways that real cohorts are not. The comparator, because "better than placebo" and "better than the current standard" are different claims and get reported identically. The primary endpoint as pre-registered, because a secondary endpoint promoted after the fact is a hypothesis rather than a finding. And the completion rate, because a large effect in the half of participants who finished is a different result from a large effect in everybody enrolled.

42 20RickReta_CO, PharmHunterJen, TomTeleRx and 39 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register